{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% Confidence Interval (CI) was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"4.3","upperLimit":"NA","value":"5.8"},{"comment":"Upper limit of 95% Confidence Interval (CI) was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"4.0","upperLimit":"NA","value":"4.7"},{"groupId":"OG002","lowerLimit":"5.7","upperLimit":"14.7","value":"9.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"50"}],"units":"Participants"}],"title":"Independent Central Review"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.7","upperLimit":"11.3","value":"5.8"},{"comment":"Upper limit of 95% Confidence Interval (CI) was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"4.2","upperLimit":"NA","value":"7.0"},{"groupId":"OG002","lowerLimit":"7.2","upperLimit":"16.9","value":"11.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"title":"Investigator Assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"50"}],"units":"Participants"}],"description":"Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \\[CR\\] or partial response \\[PR\\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on independent central review and investigator assessment is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-overexpressing(immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG000","title":"Cohort 1: HER2 Overexpressing"},{"description":"Participants with HER2-overexpressing (immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG001","title":"Cohort 1a: HER2 Overexpressing"},{"description":"Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG002","title":"Cohort 2: HER2 Mutated"}],"paramType":"MEDIAN","populationDescription":"Duration of Response (DoR) was assessed in the Full Analysis Set of participants with confirmed CR/PR at data cut-off date of 03 May 2021.","reportingStatus":"POSTED","timeFrame":"From screening to documented tumor progression or death from any cause, up to 36 months (data cut-off)","title":"Duration of Response (DoR) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)","type":"SECONDARY","unitOfMeasure":"months"}